Compare HWKN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HWKN | NRIX |
|---|---|---|
| Founded | 1938 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1995 | 2020 |
| Metric | HWKN | NRIX |
|---|---|---|
| Price | $130.45 | $22.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | ★ $174.25 | $33.93 |
| AVG Volume (30 Days) | 146.6K | ★ 1.4M |
| Earning Date | 10-26-2026 | 10-23-2026 |
| Dividend Yield | ★ 0.62% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $1,083,696,000.00 | $76,987,000.00 |
| Revenue This Year | $7.95 | $799.42 |
| Revenue Next Year | $7.46 | N/A |
| P/E Ratio | $96.69 | ★ N/A |
| Revenue Growth | 11.21 | ★ 99.31 |
| 52 Week Low | $116.05 | $9.14 |
| 52 Week High | $176.58 | $28.23 |
| Indicator | HWKN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 31.71 |
| Support Level | $130.08 | $21.23 |
| Resistance Level | $130.52 | $24.65 |
| Average True Range (ATR) | 3.37 | 0.96 |
| MACD | 0.49 | -0.14 |
| Stochastic Oscillator | 69.40 | 21.25 |
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The Industrial Solutions segment, provides industrial chemicals, products and services to industries such as industrial manufacturing, chemical processing, electronics, energy, plating, and surface finishing. The water treatment segment, which generates the majority of revenue sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. Food and Health Sciences segment specializes in processing and formulation solutions as well as ingredient distribution to manufacturers in the nutrition, food, pharmaceutical, and agricultural markets.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.